With next generation of complex immuno-oncology candidates, preclinical and translational scientists in the IO space are in need for more predictive tumour models to improve clinical translatability, accelerating speed-to-clinic with confidence.
We are excited to finally reunite this community in December at 11th PREDiCT: Tumour Models London Summit to address the critical next step of narrowing the preclinical gap and progressing efficacious candidates to the clinic.
This much-anticipated in-person meeting will unite 120+ pioneers to help you:
Benchmark against peers' in vivo and in vitro model selection strategy for novel IO, in conjunction with NK and macrophages interaction with TME, to maximise translatability
Evaluate and compare next generation tumour models for TME, cell-cell interaction, immune response and drug response to guide clinical design and patient selection
Accelerate off-the-shelf humanised and PDX model development for NK, allogenic cell therapies
Rigorously test, characterise, validate novel cancer models to support adoption and ensure quality control in preclinical studies
Engage with leading academics and CROs to drive long-term partnerships and fuel model innovations
This is your must-attend tumour model summit to reconnect with fellows from Pfizer, Sanofi, GSK, and propel your clinical progression with confidence in 2023!
Speakers: Céline Nicolazzi Group Leader Pharmacology Oncology Sanofi, Antje Margret Wengner Senior Scientist Bayer AG, Aude de Gassart Head of Preclinical Model Development ImCheck Therapeutics, Anita Seshire Head of Laboratory in Exploratory Cancer Research Merck Healthcare, Pelin Candarlioglu Cell Biologist In Complex In Vitro GSK, Andrew Pierce VP Translational Biology Cresendo Biologics, Joshua Breunig Associate Professor, Director, Brain Program Cedars-Sinai Medical Center and UCLA, Adam Drake Senior Director In Vivo Pharmacology Ichnos Sciences, Andrea Bisso Vice President Gadeta, Anil Thotakura Head of Immuno- Oncology Orion Corporation, Fernando Estrada Lecturer in Innate Immunology University of Surrey, Juho Jalkanen Chief Operating Officer Faron Pharmaceuticals, Jonathan Fisher Group Leader, Paediatric Oncologist UCL, Marta Barisa Senior Fellow Great Orman Street Institutue of Child Health (GOSH) UCL, Pierre Cordelier Pierre Cordelier Deputy Director and Team Leader ImPACT Therapeutic Innovation In Pancreatic Cancer INSERM, Jasper Mullenders Director Translational Biology Scenic Biotech, Eric Ibsen CEO Studylog, Kader Thiam SVP Preclinical Models genOway, Massimiliano Borsani Research Infrastructure Manager EuroPDX, Senior Representative Certis Oncology, Senior Representative Reaction Biology, Senior Representative inovotion, Senior Representative Miltenyi Biotec, Senior Representative Imagen, Senior Representative GemPharmatech, Senior Representative The Jackson Laboratory
ILEC Conference Centre, London
47 Lillie Road
Share this page